NASDAQ:ZIOP ZIOPHARM Oncology (ZIOP) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.82▼$1.3952-Week Range N/AVolume2.13 million shsAverage Volume2.01 million shsMarket Capitalization$187.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About ZIOPHARM Oncology (NASDAQ:ZIOP) StockZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.Read More Receive ZIOP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address ZIOP Stock News HeadlinesMay 11, 2023 | marketwatch.comNatural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.coMarch 27, 2023 | marketwatch.comGlobal Drugs for Non-small Cell Lung Cancer Market Size 2023 to 2026 Size and Share Survey ReportMay 31, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>March 27, 2023 | marketwatch.comChronic Lymphocytic Leukemia Market 2023 Size and Forecast to 2030February 23, 2023 | finance.yahoo.comUSA Community Oncology Services Market Competitor Scenario - Market Positioning And Player-Based Strategies, By The Business Research CompanyFebruary 18, 2023 | finance.yahoo.comVerdi Oncology's Horizon Oncology Announces Agreement with Integra Connect to Bring Value-Based Care to Central IndianaFebruary 18, 2023 | marketwatch.comGlobal Gene Therapy in Oncology Market Size is Booming Across the Globe and Witness Huge Growth by Key Players to 2030 By VMReportsFebruary 18, 2023 | seekingalpha.comiBio shares more than double in value after hours on new immuno-oncology target programMay 31, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>January 24, 2023 | marketwatch.comCancer Care Market is booming in near Future 2023-2028January 13, 2023 | finanznachrichten.deNerviano Medical Sciences S.r.l.: Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor AssetJanuary 12, 2023 | yahoo.comNerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor AssetJanuary 5, 2023 | thestreet.comZiopharm Subpar Cancer Therapies Can't Support Lofty Market ValuationNovember 26, 2022 | marketwatch.comCancer Care Market : Share, Industry Size, Opportunities, Analysis and Forecast to 2028 with Top Countries DataNovember 12, 2022 | finance.yahoo.comOncology Clinician-Scientist Jason Luke, MD Named physIQ Medical AdvisorOctober 20, 2022 | finance.yahoo.comGadeta Appoints Scientific Advisory Board and Provides Business UpdateSeptember 27, 2022 | marketwatch.comGlobal Cancer Care Market Size and Scope 2022 Research Report by Consumption, Revenue, Regions, Gross Margin and Forecast to 2026September 24, 2022 | finanznachrichten.deCelyad Oncology SA: Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations TransactionSeptember 7, 2022 | finance.yahoo.comCandel Therapeutics Announces Two Executive Leadership AppointmentsSeptember 2, 2022 | thestreet.comWhy This Fund Manager Is Short ZiopharmAugust 25, 2022 | thestreet.comBiotech Stock Mailbag: Ziopharm, Oncolytics, SareptaAugust 22, 2022 | finance.yahoo.comGlobal Allogeneic Cell Therapy Market Size-Forecasts to 2027August 18, 2022 | fool.comZIOPHARM Oncology (NASDAQ: ZIOP)August 9, 2022 | sg.finance.yahoo.comNorth America oncology market value to cross USD 246 billion by 2028August 3, 2022 | marketwatch.comTesticular Cancer Drugs Market is Booming Right Now, let's Understand Market Size, Share and Forecast till 2028July 15, 2022 | marketwatch.comGene Therapies for Cancer Treatment Market to Garner Considerable Growth at a higher % of CAGR During the Study Period 2022-2028July 15, 2022 | marketwatch.comTesticular Cancer Drugs Market Size 2022 Report by Industrial Growth, Share, Emerging Trends, Latest Development, Segmentations and Forecast to 2028See More Headlines Receive ZIOP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address ZIOP Company Calendar Last Earnings11/08/2021Today5/31/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ZIOP CUSIP98973P10 CIK1107421 Webwww.ziopharm.com Phone(617) 259-1970Fax617-241-2855Employees105Year Founded2005Profitability EPS (Most Recent Fiscal Year)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-79,980,000.00 Net MarginsN/A Pretax Margin-22,544.97% Return on Equity-92.84% Return on Assets-72.46% Debt Debt-to-Equity Ratio0.18 Current Ratio3.43 Quick Ratio3.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / BookN/AMiscellaneous Outstanding Shares216,146,000Free Float204,906,000Market Cap$187.12 million OptionableOptionable Beta1.71 Social Links Key ExecutivesKevin S. BoyleChief Executive Officer & DirectorTimothy M. CunninghamChief Financial OfficerLynn M. FerrucciEVP-Human Resources, Administration & ITRaffaele BaffaChief Medical Officer & Head-ResearchEleanor M. de GrootGeneral Manager-Cell Therapy & Executive VPKey CompetitorsMerrimack PharmaceuticalsNASDAQ:MACKXOMANASDAQ:XOMAVerastemNASDAQ:VSTMSpectrum PharmaceuticalsNASDAQ:SPPIRigel PharmaceuticalsNASDAQ:RIGLView All Competitors ZIOP Stock - Frequently Asked Questions How were ZIOPHARM Oncology's earnings last quarter? ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) issued its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. The biotechnology company earned $0.40 million during the quarter. During the same period in the previous year, the company posted ($0.10) earnings per share. What other stocks do shareholders of ZIOPHARM Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN), Gilead Sciences (gild), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Inovio Pharmaceuticals (INO), Arena Pharmaceuticals (ARNA) and Immunomedics (IMMU). What is ZIOPHARM Oncology's stock symbol? ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP." How much money does ZIOPHARM Oncology make? ZIOPHARM Oncology (NASDAQ:ZIOP) has a market capitalization of $0.00. The biotechnology company earns $-79,980,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. How many employees does ZIOPHARM Oncology have? The company employs 105 workers across the globe. How can I contact ZIOPHARM Oncology? ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The official website for the company is www.ziopharm.com. The biotechnology company can be reached via phone at (617) 259-1970, via email at dconnolly@ziopharm.com, or via fax at 617-241-2855. This page (NASDAQ:ZIOP) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZIOPHARM Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.